SG Americas Securities LLC Has $658,000 Position in Denali Therapeutics Inc. (NASDAQ:DNLI)

SG Americas Securities LLC grew its holdings in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 339.6% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 48,365 shares of the company's stock after purchasing an additional 37,362 shares during the period. SG Americas Securities LLC's holdings in Denali Therapeutics were worth $658,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Rhumbline Advisers lifted its stake in Denali Therapeutics by 0.3% in the 4th quarter. Rhumbline Advisers now owns 190,390 shares of the company's stock valued at $3,880,000 after purchasing an additional 497 shares during the last quarter. PNC Financial Services Group Inc. increased its holdings in shares of Denali Therapeutics by 30.5% during the fourth quarter. PNC Financial Services Group Inc. now owns 3,790 shares of the company's stock worth $77,000 after buying an additional 885 shares in the last quarter. Sterling Capital Management LLC lifted its stake in shares of Denali Therapeutics by 589.9% in the 4th quarter. Sterling Capital Management LLC now owns 1,773 shares of the company's stock valued at $36,000 after acquiring an additional 1,516 shares during the last quarter. The Manufacturers Life Insurance Company lifted its stake in shares of Denali Therapeutics by 0.8% in the 4th quarter. The Manufacturers Life Insurance Company now owns 208,521 shares of the company's stock valued at $4,250,000 after acquiring an additional 1,702 shares during the last quarter. Finally, E Fund Management Co. Ltd. boosted its holdings in shares of Denali Therapeutics by 32.2% during the 4th quarter. E Fund Management Co. Ltd. now owns 9,997 shares of the company's stock valued at $204,000 after acquiring an additional 2,436 shares in the last quarter. Institutional investors own 92.92% of the company's stock.

Denali Therapeutics Trading Up 0.3%

DNLI stock traded up $0.05 during midday trading on Wednesday, hitting $14.45. The stock had a trading volume of 1,110,452 shares, compared to its average volume of 1,124,194. The firm has a market cap of $2.10 billion, a P/E ratio of -5.41 and a beta of 1.32. The business has a fifty day moving average price of $14.35 and a two-hundred day moving average price of $17.29. Denali Therapeutics Inc. has a 1-year low of $10.57 and a 1-year high of $33.33.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported ($0.78) earnings per share for the quarter, missing the consensus estimate of ($0.71) by ($0.07). During the same period in the previous year, the company earned ($0.68) earnings per share. On average, equities analysts anticipate that Denali Therapeutics Inc. will post -2.71 EPS for the current year.

Wall Street Analysts Forecast Growth

DNLI has been the subject of a number of recent research reports. Oppenheimer lowered their target price on Denali Therapeutics from $50.00 to $42.00 and set an "outperform" rating for the company in a report on Monday, March 3rd. Wedbush dropped their price objective on shares of Denali Therapeutics from $32.00 to $30.00 and set an "outperform" rating for the company in a report on Wednesday, May 7th. William Blair upgraded shares of Denali Therapeutics to a "strong-buy" rating in a report on Thursday, April 24th. Cantor Fitzgerald raised shares of Denali Therapeutics from a "neutral" rating to an "overweight" rating in a report on Thursday, April 10th. Finally, B. Riley restated a "buy" rating and issued a $35.00 price target (down from $38.00) on shares of Denali Therapeutics in a research report on Wednesday, March 5th. One analyst has rated the stock with a hold rating, fourteen have given a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $33.71.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.